Erythrocin Stearate

Gastroparesis, Erythrasma, Whooping Cough + 60 more

Treatment

68 FDA approvals

20 Active Studies for Erythrocin Stearate

What is Erythrocin Stearate

Erythromycin

The Generic name of this drug

Treatment Summary

Erythromycin is an antibiotic used to treat bacterial infections. It was discovered in 1952 and belongs to a group of antibiotics known as macrolides. Erythromycin is used to treat infections caused by both gram-positive and gram-negative bacteria. It can be taken in various forms, such as intravenous, topical, and eye drops.

Erythrocin Stearate

is the brand name

image of different drug pills on a surface

Erythrocin Stearate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Erythrocin Stearate

Erythromycin

1964

261

Approved as Treatment by the FDA

Erythromycin, also known as Erythrocin Stearate, is approved by the FDA for 68 uses which include Acne Vulgaris and Acne Vulgaris .

Acne Vulgaris

Used to treat Acne Vulgaris in combination with Tretinoin

Acne Vulgaris

Used to treat predominant skin comedones, papules and pustules in combination with Tretinoin

Corynebacterium Infections

Urethritis

Staphylococcus (S.) Aureus Infection

urogenital infections during pregnancy

Pertussis

treponema pallidum infection

Diphtheria

penicillins

Bacterial Infections

Communicable Diseases

Conjunctivitis

Respiratory Tract Infections

Erythrasma

Postoperative Infections

Listeriosis

Corynebacterium minutissimum infection

Recurrent Upper and Lower Respiratory Tract Infections (RTIs)

Pneumonia, Mycoplasma

Whooping Cough

Bordetella Pertussis Infection

uncomplicated endocervical infection

Staphylococcal Skin Infections

Communicable Diseases

pustular lesions

Used to treat pustular lesions in combination with Avobenzone

Communicable Diseases

Bacterial Infections

Whooping Cough

Pneumonia

Listeria infection

Listeria monocytogenes infection

Acute Otitis Media caused by Haemophilus Influenzae

Used to treat Acute Otitis Media caused by Haemophilus Influenzae in combination with Sulfisoxazole

inflammatory papular lesions

Used to treat inflammatory papular lesions in combination with Avobenzone

Amebiasis

Common Cold

Rheumatic Fever

prophylaxis of Postoperative Infections

Communicable Diseases

prophylaxis of Rheumatic fever

Ureaplasma urethritis

penicillins

Upper Respiratory Tract Infection

Streptococcus Pneumoniae Infections

Streptococcus pyogenes

Staphylococcal Skin Infections

Urethritis

Urinary Tract Infection (UTI)

Legionella pneumophila

Primary Syphilis

Lower Respiratory Tract Infection (LRTI)

Intestinal amebiasis caused by entamoeba histolytica

Skin and skin structure infections

Corynebacterium Infections

diphtheria antitoxin

Bronchitis

Haemophilus Influenzae Infections

Used to treat Haemophilus Influenzae Infections in combination with null

Urethritis

Ureaplasma urealyticum

skin and subcutaneous tissue bacterial infections caused by streptococcus pyogenes

Whooping Cough

Chlamydia Trachomatis

patients with intolerance or contraindications to tetracycline use

Syphilis

First episode of rheumatic fever

Rheumatic Fever

Pneumococcal Infections

Sulfonamides

Effectiveness

How Erythrocin Stearate Affects Patients

Erythromycin is a type of antibiotic that treats bacterial infections by stopping the growth and spread of bacteria. It is important to test the bacteria to make sure it is susceptible to erythromycin before administering the drug. Some strains of Haemophilus influenzae are resistant to erythromycin but may be sensitive to erythromycin and sulfonamides used in combination. It is important to note that Staphylococci that are resistant to erythromycin may emerge during erythromycin and/or sulfonamide therapy. Taking erythromycin may cause

How Erythrocin Stearate works in the body

Erythromycin works by preventing bacteria from making proteins. It binds to the ribosomes in the bacteria, which are responsible for making proteins. This stops the bacteria from making proteins and ultimately kills them, controlling bacterial infections. This drug has a strong affinity for bacterial ribosomes, which is why it is effective against such a wide range of bacterial infections.

When to interrupt dosage

The prescribed measure of Erythrocin Stearate is subject to the diagnosed condition, such as Chlamydia Trachomatis, penicillins and Syphilis. The dosage may differ in line with the technique of administration (e.g. Granule, for suspension or Tablet, film coated - Oral), as specified in the table underneath.

Condition

Dosage

Administration

Granuloma Inguinale

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Urethritis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Acne Vulgaris

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Respiratory Tract Infections

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Endophthalmitis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Ophthalmia neonatorum (gonococcal)

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Conjunctivitis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Amebiasis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Rheumatic Fever

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Communicable Diseases

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Acne Vulgaris

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Chlamydia Trachomatis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Streptococcus pyogenes

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

diphtheria antitoxin

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

urogenital infections during pregnancy

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Syphilis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Acne Vulgaris

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Communicable Diseases

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Rheumatic Fever

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Corynebacterium Infections

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Warnings

Erythrocin Stearate has nine contraindications, so its usage should be avoided when confronting any of the conditions listed in the following table.

Erythrocin Stearate Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Erythromycin may interact with Pulse Frequency

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Erythrocin Stearate.

Common Erythrocin Stearate Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Erythromycin.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Erythromycin.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Erythromycin.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Erythromycin.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Erythromycin.

Erythrocin Stearate Toxicity & Overdose Risk

The toxic dose of erythromycin for rats is 9272 mg/kg. Taking too much erythromycin can cause diarrhea, nausea, stomach cramps, and vomiting. If an overdose occurs, the drug should be stopped right away and any unabsorbed drug should be removed as quickly as possible. Supportive treatments may also be necessary. Unfortunately, neither peritoneal dialysis nor hemodialysis are able to remove erythromycin from the body.

Erythrocin Stearate Novel Uses: Which Conditions Have a Clinical Trial Featuring Erythrocin Stearate?

Currently, 53 active trials are assessing the potential of Erythrocin Stearate as a treatment for Streptococcus pyogenes, Treponema pallidum infection and Rheumatic Fever.

Condition

Clinical Trials

Trial Phases

Acne Vulgaris

3 Actively Recruiting

Phase 1, Phase 2, Early Phase 1, Phase 4

Listeriosis

0 Actively Recruiting

Legionella pneumophila

0 Actively Recruiting

Urethritis

0 Actively Recruiting

Ureaplasma urealyticum

0 Actively Recruiting

Acute Otitis Media caused by Haemophilus Influenzae

0 Actively Recruiting

Gastroparesis

14 Actively Recruiting

Phase 3, Not Applicable, Phase 1, Early Phase 1

Acne Vulgaris

0 Actively Recruiting

Pneumococcal Infections

0 Actively Recruiting

Corynebacterium minutissimum infection

0 Actively Recruiting

Acne Vulgaris

0 Actively Recruiting

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Urethritis

0 Actively Recruiting

Listeria monocytogenes infection

0 Actively Recruiting

Chlamydia Trachomatis

0 Actively Recruiting

Conjunctivitis

0 Actively Recruiting

penicillins

1 Actively Recruiting

Phase 3

Primary Syphilis

0 Actively Recruiting

treponema pallidum infection

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Erythrocin Stearate Reviews: What are patients saying about Erythrocin Stearate?

2.3

Patient Review

8/29/2008

Erythrocin Stearate for Strep Throat

This gave me a burning feeling in my stomach and rectum. It also made me bleed.

2

Patient Review

10/1/2012

Erythrocin Stearate for Acne

I went to my doctor because I had a painful boil on my face and something in my ear. He prescribed this medication, but instead of helping the situation, it caused another boil to form; which was even larger and more painful than the first one. He then lanced the boil, but nothing came out. The dosage of this medication was decreased as a result. However, now I am experiencing severe hair loss! I am 18 years old and I am really upset! I have a bald spot on my right temple; the size of a quarter. Hopefully my hair will grow back.

2

Patient Review

4/20/2010

Erythrocin Stearate for Stomach Muscle Paralysis and Decreased Function

I was recommended this medicine as an alternative to Reglan, but I found it did not work well for me. I had to cut the pills in half because they do not make the dosage that was prescribed for me, and this made them difficult to take. I felt more sick after taking this pill than I did before, so I have stopped taking it altogether. It seems like there should be more studies done on this very debilitating condition!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about erythrocin stearate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What class of drug is erythromycin stearate?

"Erythromycin is an antibiotic that slows the growth of bacteria."

Answered by AI

What is erythromycin stearate drug used for?

"Erythromycin is a medication used to treat many different types of bacterial infections. It can also be taken to prevent certain bacterial infections from occurring. Erythromycin is said to be a macrolide antibiotic. This means that it works by stopping the growth of bacteria."

Answered by AI

What is the difference between erythromycin and erythromycin stearate?

"The traditional antibiotic for treating pertussis is oral erythromycin. Erythromycin estolate is considered more effective than erythromycin ethylsuccinate or erythromycin stearate because it results in higher concentrations of the drug in the bloodstream and respiratory secretions."

Answered by AI

Is Erythrocin and erythromycin the same?

"Erythrocin Stearate Film-coated tablets are an antibacterial product containing the stearate salt of erythromycin in a unique film coating. This film coating helps the erythromycin to be absorbed by the body more slowly, which reduces the possibility of side effects."

Answered by AI

Clinical Trials for Erythrocin Stearate

Image of Children's Healthcare of Atlanta in Atlanta, United States.

Antibiotic Strategies for Pneumonia in Children

12 - 71
All Sexes
Atlanta, GA

The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with community-acquired pneumonia get better from their illness. The main aims of this study are: * To compare the effectiveness of SNAP versus immediate antibiotic prescribing in children with mild community-acquired pneumonia (CAP) * To identify which patient groups benefit most from the SNAP strategy * To identify factors that shape implementation of each prescribing strategy. Researchers will compare the SNAP strategy (where parents or guardians are instructed to give antibiotics only if their child is not improving after 72 hours, or sooner if they are worsening) to the immediate antibiotic prescribing strategy (where parents or guardians are instructed to give the antibiotics right after their healthcare visit) to see if one strategy is more effective than the other. Participants will be randomly assigned to either the immediate antibiotic group or the SNAP group at enrollment. Participation lasts 14 days with follow-up surveys at 4, 7, and 14 days after enrollment.

Recruiting
Has No Placebo

Children's Healthcare of Atlanta (+3 Sites)

Todd Florin, MD, MSCE

Have you considered Erythrocin Stearate clinical trials?

We made a collection of clinical trials featuring Erythrocin Stearate, we think they might fit your search criteria.
Go to Trials
Image of Children's Community Pediatrics Brentwood in Pittsburgh, United States.

AI Diagnostic Support for Ear Infections

6 - 24
All Sexes
Pittsburgh, PA

Ear infections are common in young children with cold symptoms, but they can be difficult to diagnose due to small ear canals, child movement, and limited viewing time. In this study, investigators will take photos of the eardrums of children 6-24 months of age with upper respiratory symptoms. The photos will be reviewed by imaging software enhanced with artificial intelligence (AI app) to determine whether the AI app changes how ear infections are diagnosed and treated. The AI app has undergone rigorous study and was found to be highly accurate; but how using this technology affects the diagnosis and treatment by clinicians has not been studied. This research may help improve diagnostic accuracy for ear infections and ensure antibiotics are prescribed only for those children who have definite ear infections.

Recruiting
Has No Placebo

Children's Community Pediatrics Brentwood (+1 Sites)

Timothy R Shope, MD, MPH

Merck Sharp & Dohme LLC

Image of Maternity Centre of Hamilton in Hamilton, Canada.

Rapid Test for Syphilis

13 - 49
All Sexes
Hamilton, Canada

The goal of this clinical trial is to learn if a finger-prick blood test for rapid diagnosis of syphilis infection can be implemented in a low-barrier prenatal clinic for people at risk of syphilis in pregnancy. The test gives results in 5 minutes and also tests for HIV. The main questions the study aims to answer are: * How often do pregnant people at risk of syphilis agree to the rapid test? * How well do healthcare providers perform the rapid test? * Does the rapid test speed up diagnosis and treatment of syphilis in pregnant people and their sexual partners? Participants will: * Give feedback about why they did or did not want to take the rapid test, and what their experience was taking the test; and * Share information about their health, pregnancy, and syphilis treatment (if applicable).

Recruiting
Has No Placebo

Maternity Centre of Hamilton

Laura K Erdman, MD PhD FRCPC

Image of Benioff Children's Hospital - Oakland in Oakland, United States.

Decision Support for Lower Respiratory Infections in Children

6 - 17
All Sexes
Oakland, CA

Eliminating inappropriate antibiotic use in pediatric lower respiratory tract infections (LRTI) is the central focus of this research. LRTIs (pneumonia, bronchiolitis, and infection-related exacerbations of asthma) account for nearly one-third of all emergency department (ED) visits and 40% of all infection-related hospitalizations in US children. LRTIs also account for more antibiotic use in children's hospitals than any other condition, despite most LRTIs being viral in nature. Inappropriate antibiotics are associated with substantial adverse effects. Accordingly, national guidelines strongly discourage routine antibiotic use for bronchiolitis and acute asthma and argue for significantly reducing antibiotic exposure (initiation, spectrum, and duration) in pneumonia. To address the problem of inappropriate antibiotic use, hospital-based antimicrobial stewardship programs (ASPs) are now common nationwide, and these programs have demonstrated effectiveness in some hospital settings. Unfortunately, traditional ASP approaches do not translate well to the fast-paced and unpredictable ED environment, and hospital-based ASP resources are finite and not always immediately available. Clinical decision support (CDS) embedded within the electronic health record (EHR) is a strategy that could address the ED antibiotic stewardship gap. Informed by a deep understanding of the key facilitators and barriers to using CDS to support appropriate antibiotic use in ED and hospital settings, the investigators have developed two stewardship-focused CDS interventions for pediatric LRTI. The overarching goal of this research is to rigorously evaluate the implementation and effectiveness of these CDS tools, alone and in combination, against usual care only in a pragmatic randomized clinical trial at 3 U.S. children's hospitals.

Recruiting
Has No Placebo

Benioff Children's Hospital - Oakland (+2 Sites)

Derek J Williams, MD, MPH

Have you considered Erythrocin Stearate clinical trials?

We made a collection of clinical trials featuring Erythrocin Stearate, we think they might fit your search criteria.
Go to Trials
Image of University of Pennsylvania Primary Care Practice in Philadelphia, United States.

Rapid Testing for Upper Respiratory Tract Infection

18+
All Sexes
Philadelphia, PA

The goal of this study is to understand the use of point of care (POC) testing devices in primary care offices to help clinicians diagnose and appropriately treat patients who have symptoms of upper respiratory infections (URIs). The study will use the BIOFIRE® SPOTFIRE® Respiratory (R) Panel testing device, which is FDA-cleared and CLIA-Waived. This panel can identify up to 15 different viruses and bacteria that can cause URIs. These POC devices will be installed in primary care clinics within the University of Pennsylvania Health System. Patients who come to the clinic with cold-like symptoms (runny nose, cough) will be offered the test. If the patient agrees to the test, their clinician will use a swab to take a small sample of fluid from their nose. This swab will then be tested within the POC device and results will be available within 15 minutes. The results of this sample will be shared with the patient, and their clinician can use the results to help decide the most appropriate medical treatment for the patient. Patients who agree to take the test will be asked to answer a short survey about the test and their experience. Clinicians will also be surveyed to share their thoughts with using the test in their clinics. Focus groups of practice staff and clinicians will also be conducted to understand any potential challenges for using this test in practice. Results from the tests and the surveys will help researchers understand the value of the test to support antibiotic stewardship efforts in primary care clinic settings.

Waitlist Available
Has No Placebo

University of Pennsylvania Primary Care Practice

Have you considered Erythrocin Stearate clinical trials?

We made a collection of clinical trials featuring Erythrocin Stearate, we think they might fit your search criteria.
Go to Trials